NASDAQ:BCRX

Biocryst Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy BCRX

*Your capital is at risk

$8.25

-0.0900 (-1.08%)

At Close: Jun 03, 2026

BioCryst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -8.99. In total, the insiders bought 6.54M and sold 1.09M BCRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-8.99
● Buy	6.54M shares
● Sell	1.09M shares
80% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 13, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 13, 2025 Buy	Automatic Stock Option Grant M-Exempt	Heggie Theresa Director	Director	40 000 Value: $216.4K
Aug 13, 2025 Buy	Automatic Stock Option Grant M-Exempt	Heggie Theresa Director	Director	30 000 Value: $87.3K
Aug 13, 2025 Sell	Common Stock S-Sale	Heggie Theresa Director	Director	70 000 Value: $595.9K
Aug 13, 2025 Buy	Common Stock M-Exempt	Heggie Theresa Director	Director	30 000 Value: $87.3K
Aug 13, 2025 Buy	Common Stock M-Exempt	Heggie Theresa Director	Director	40 000 Value: $216.4K
Jul 24, 2025 Buy	Emp. Stock Option (Right to Buy) A-Award	Ghias Babar CFO & Head Of Corp Development	C-Suite Officer	305 000 Value: $2.61M
Jul 24, 2025 Buy	Common Stock A-Award	Ghias Babar CFO & Head Of Corp Development	C-Suite Officer	147 000 Value: $1.26M
Jul 24, 2025 Buy	Common Stock A-Award	Ghias Babar CFO & Head Of Corp Development	C-Suite Officer	147 000 Value: $1.26M
Jul 24, 2025 Buy	Emp. Stock Option (Right to Buy) A-Award	Ghias Babar CFO & Head Of Corp Development	C-Suite Officer	305 000 Value: $2.61M
Jul 07, 2025 Buy	Common Stock J-Other	Ghias Babar Officer	Officer	0 Value: $0
Jul 07, 2025 Buy	Common Stock J-Other	Ghias Babar Officer	Officer	0 Value: $0
Jun 12, 2025 Buy	Automatic Stock Option Grant A-Award	Hutson Nancy J Director	Director	27 181 Value: $282.7K
Jun 12, 2025 Buy	Common Stock A-Award	Hutson Nancy J Director	Director	12 500 Value: $130.0K
Jun 12, 2025 Buy	Automatic Stock Option Grant A-Award	Levin Alan G Director	Director	27 181 Value: $282.7K
Jun 12, 2025 Buy	Common Stock A-Award	Levin Alan G Director	Director	12 500 Value: $130.0K
Jun 12, 2025 Buy	Automatic Stock Option Grant A-Award	Mckee Amy E Director	Director	27 181 Value: $282.7K
Jun 12, 2025 Buy	Common Stock A-Award	Mckee Amy E Director	Director	12 500 Value: $130.0K
Jun 12, 2025 Buy	Automatic Stock Option Grant A-Award	Milano Vincent Director	Director	27 181 Value: $282.7K
Jun 12, 2025 Buy	Common Stock A-Award	Milano Vincent Director	Director	12 500 Value: $130.0K
Jun 12, 2025 Buy	Automatic Stock Option Grant A-Award	Sanders Machelle Director	Director	27 181 Value: $282.7K
Dec 14, 2024 Buy	Emp. Stock Option (Right to Buy)	Dullinger Ronald Chief Commercial Officer	Officer	57 100 Value: $367.2K
Dec 19, 2023 Buy	Emp. Stock Option (Right to Buy)	Dullinger Ronald Chief Commercial Officer	Officer	57 100 Value: $607.0K
Dec 14, 2022 Buy	Emp. Stock Option (Right to Buy)	Dullinger Ronald Chief Commercial Officer	Officer	41 000 Value: $468.6K
Dec 15, 2021 Buy	Emp. Stock Option (Right to Buy)	Dullinger Ronald Chief Commercial Officer	Officer	100 000 Value: $831.0K
Nov 29, 2020 Buy	Emp. Stock Option (Right to Buy)	Dullinger Ronald Chief Commercial Officer	Officer	100 000 Value: $285.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOCRYST PHARMACEUTICALS

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...

Read Full Profile Here